Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1632 1638 1641 1651 1655
This examiner grants 39% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18029354 | METHOD FOR CRYOPRESERVING A PLURALITY OF CELL CLUSTERS OF BIOLOGICAL CELLS | Non-Final OA | Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e. V. |
| 18018389 | CELL CULTURE MEDIA AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | AMGEN INC. |
| 18284060 | VENO-ARTERIAL VENOUS CROSS-CIRCULATION FOR EXTRACORPOREAL ORGAN SUPPORT | Non-Final OA | VANDERBILT UNIVERSITY |
| 16422086 | PATCH GRAFT COMPOSITIONS FOR CELL ENGRAFTMENT | Final Rejection | The University of North Carolina at Chapel Hill |
| 18558065 | STRING-LIKE AGGREGATES OF RETINAL PIGMENT EPITHELIAL CELLS, DEVICE AND PRODUCTION METHOD FOR PRODUCING SAME, AND THERAPEUTIC AGENT COMPRISING SAID STRING-LIKE AGGREGATES | Non-Final OA | RIKEN |
| 18560000 | Methods and Compositions for Extending Organ and Tissue Preservation | Non-Final OA | The General Hospital Corporation |
| 19028696 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING AND PREVENTING HALITOSIS | Non-Final OA | Imvela Corp. |
| 18790185 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING AND PREVENTING HALITOSIS | Final Rejection | Imvela Corp. |
| 16089918 | METHOD OF PRODUCING SUGAR LIQUID | Non-Final OA | Toray Industries, Inc. |
| 18608371 | PLACENTAL TISSUE PARTICULATE COMPOSITIONS AND METHODS OF USE | Non-Final OA | Musculoskeletal Transplant Foundation |
| 17778333 | PLACENTAL TISSUE PARTICULATE COMPOSITIONS AND METHODS OF USE | Non-Final OA | Musculoskeletal Transplant Foundation |
| 18016978 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DIABETES | Final Rejection | OSAKA UNIVERSITY |
| 17642809 | HER3 PULSED DC1 THERAPY | Final Rejection | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18124110 | METHODS AND COMPOSITIONS FOR INHIBITING ICE RECRYSTALLIZATION | Final Rejection | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION |
| 18038088 | DENSITY-ADJUSTED LIQUIDS AND METHODS USING SAME | Non-Final OA | STEMCELL TECHNOLOGIES CANADA INC. |
| 18584293 | IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS | Non-Final OA | OSIRIS THERAPEUTICS, INC. |
| 18584350 | IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS | Final Rejection | OSIRIS THERAPEUTICS, INC. |
| 17440991 | Enhanced Transfection | Final Rejection | The University of Nottingham |
| 17291536 | PROCESS FOR PRODUCING GENETICALLY ENGINEERED T CELLS | Non-Final OA | Juno Therapeutics, Inc. |
| 18270924 | CELLULAR MICROCOMPARTMENTS COMPRISING CELLS OF WHICH THE GENOMIC INTEGRITY IS MAINTAINED AFTER AMPLIFICATION AND PREPARATION METHOD | Non-Final OA | TREEFROG THERAPEUTICS |
| 18060626 | HISTAMINE-PRODUCING BACTERIAL STRAINS AND THEIR USE IN CANCER | Non-Final OA | BIOGAIA AB |
| 18044955 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | Non-Final OA | BioNTech SE |
| 18024839 | BIOMIMETIC WOUND HEALING DEVICES AND RELATED METHODS OF TREATING DIABETIC WOUNDS | Non-Final OA | Protein Genomics Inc. |
| 18024012 | ENHANCED EXPANSION AND CYTOTOXICITY OF ENGINEERED NATURAL KILLER CELLS AND USES THEREOF | Non-Final OA | Nkarta, Inc. |
| 18022159 | COLLOIDAL SOLUTION FOR EX-VIVO LUNG PERFUSION AND STORAGE | Final Rejection | S.A.L.F. S.p.A. Laboratorio Farmacologico |
| 18012904 | CRYOPRESERVATION METHOD FOR ORGAN-ON-A-CHIP | Non-Final OA | MEPSGEN CO., LTD. |
| 16634820 | COMPOSITION FOR CRYOPRESERVATION, METHOD FOR PRODUCING CRYOPRESERVED MATERIAL, CELL PREPARATION, METHOD FOR PRODUCING CELL PREPARATION, AND KIT FOR CRYOPRESERVATION | Final Rejection | TWO CELLS Co., Ltd. |
| 17088860 | ICE-FREE VITRIFICATION AND NANO WARMING OF LARGE TISSUE SAMPLES | Non-Final OA | LifeNet Health |
| 17998199 | PLACENTA-DERIVED ADHERENT (PDA) STEM CELL FOR THE TREATMENT OF ADULTS WITH SARS-COV-2 RELATED ACUTE RESPIRATORY FAILURE AND ARDS (COVID-19) | Non-Final OA | Celularity Inc. |
| 17915767 | PHARMACEUTICAL COMPOSITION AND METHOD FOR INDUCING AN IMMUNE RESPONSE | Non-Final OA | R.G.C.C. Holdings AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy